Pediatric Cytomegalovirus Infection Medication: Antiviral Agents, Immunoglobulins (original) (raw)

Medication Summary

Experience with antiviral agents for cytomegalovirus (CMV) prophylaxis and CMV therapy is limited in children. Administer anti-CMV therapy only after consultation with an expert familiar with dosages and adverse effects. Antiviral agents may be administered therapeutically for established CMV disease or prophylactically (ie, preemptive therapy) when the risk of development of CMV disease is high (eg, in transplant recipients).

eMedicine Logo

Antiviral Agents

Class Summary

Nucleosides are the only true antiviral agents active against cytomegalovirus (CMV), although immunoglobulins may provide some antiviral effect, particularly in combination with these agents. These agents share a common molecular target, namely, the viral DNA polymerase. Biochemically, ganciclovir is an acyclic nucleoside analog, whereas cidofovir is an acyclic nucleoside phosphonate. Each compound must be phosphorylated to a triphosphate form before it can inhibit the CMV polymerase. A viral gene product, the UL97 phosphotransferase, mediates the monophosphorylation step for ganciclovir. In contrast to these 2 agents, foscarnet is not a true nucleoside analog but can also directly inhibit the viral polymerase.

Ganciclovir is commonly used as preemptive therapy in transplant recipients at high risk of developing disease (eg, a CMV-seronegative recipient of an organ transplant from a CMV-seropositive donor). Oral and intravenous acyclovir have also been used successfully as prophylaxis for solid organ transplantation (seronegative recipient); however, never use acyclovir for CMV therapy in active disease. An oral formulation is approved for use in adult patients infected with HIV who have CMV retinitis; however, the bioavailability is poor, and no data support use in children.

Relatively little information is available concerning the use of ganciclovir in the setting of congenital CMV infection. However, one national collaborative prospective study did demonstrate a benefit of intravenous ganciclovir in infants with symptomatic congenital CMV infection. Antiviral treatment in this study led to improvement or stabilization of hearing. [9] Follow-up studies suggested further neurodevelopmental benefits in treated infants. In light of these data, ganciclovir therapy should probably be offered for all infants with symptomatic congenital CMV infection, toward the goal of improving the neurodevelopmental prognosis of these infants. Ganciclovir therapy should also be used in infants with congenital or perinatally acquired infection with severe end-organ disease, such as pneumonia, hepatitis, or viremia. It is unclear at this time if ganciclovir benefits the long-term prognosis of an infant with asymptomatic congenital CMV infection.

Alternatives to ganciclovir include trisodium phosphonoformate (PFA) and cidofovir. Pediatric experience with these agents is limited. Although potentially useful in the setting of ganciclovir resistance, the toxicities of these antivirals are significant. Use these agents only in pediatric patients in exceptional circumstances. Although they have only a modest level of activity against CMV, high-dose oral acyclovir and valacyclovir have been used for prophylaxis of CMV disease in high-risk individuals but are not suitable for therapy of active disease. Oral therapy with valganciclovir is considered investigational in children.

Ganciclovir (Cytovene)

Ganciclovir is the first compound licensed for the treatment of CMV infections. It is a synthetic acyclic nucleotide structurally similar to guanine. Its structure is similar to that of acyclovir; like acyclovir, it requires phosphorylation for antiviral activity. The enzyme responsible for phosphorylation is the product of the viral UL97 gene, a protein kinase. Resistance may occur with long-term use, generally because of mutations in UL97.

It is indicated in immunocompromised children (eg, HIV infection, posttransplantation, other immunocompromised states) when clinical and virological evidence of specific end-organ disease (eg, pneumonitis, enteritis) is present.

In infants, antiviral therapy with ganciclovir may be of benefit in reducing the prevalence of neurodevelopmental sequelae, in particular sensorineural hearing loss. A study sponsored by the National Institutes of Allergy and Infectious Diseases demonstrated improved hearing-related outcomes in infants with symptomatic congenital CMV treated with ganciclovir. Therefore, therapy in newborns with documented infection should be considered; however, consult an expert.

Cidofovir (Vistide)

Cidofovir is a nucleotide analog that selectively inhibits viral DNA production in CMV and other herpes viral infections.

Foscarnet (Foscavir)

Foscarnet is an organic analog of inorganic pyrophosphate that inhibits replication of known herpesviruses, including CMV, HSV-1, and HSV-2. It inhibits viral replication at the pyrophosphate-binding site on virus-specific DNA polymerases.

eMedicine Logo

Immunoglobulins

Class Summary

These agents are used as passive immunization for the prevention of symptomatic cytomegalovirus (CMV) disease. This strategy has been useful in the control of CMV disease in immunocompromised patients in the prenucleoside antiviral era. It is controversial whether the infusion of CMV immune globulin in women with evidence of a primary CMV infection during pregnancy can prevent transmission and/or improve neurological outcomes in newborn infants, although this intervention is currently being investigated in several clinical trials.

Immune globulin intravenous (Carimune, Gamimune, Gammagard S/D, Gammar-P, Polygam S/D)

The observation that random donor intravenous immune globulin appears to be equal in efficacy to CMV hyperimmunoglobulin suggests that the benefit may be derived from an immunomodulatory effect unrelated to virus neutralization.

Cytomegalovirus immunoglobulin (CytoGam)

A CMV hyperimmunoglobulin has been shown to decrease the prevalence of CMV disease when administered posttransplantation to high-risk transplant recipients when administered alone or in combination with nucleoside antivirals. It may be administered therapeutically in combination with ganciclovir for CMV disease.

eMedicine Logo

  1. Schleiss MR. Persistent and recurring viral infections: the human herpesviruses. Curr Probl Pediatr Adolesc Health Care. 2009 Jan. 39(1):7-23. [QxMD MEDLINE Link].
  2. Soderberg-Naucler C. Does cytomegalovirus play a causative role in the development of various inflammatory diseases and cancer?. J Intern Med. 2006 Mar. 259(3):219-46. [QxMD MEDLINE Link].
  3. Goodpasture EQ, Talbot FB. Concerning the nature of "protozoan-like" cells in certain lesions of infancy. Am J Dis Child. 1921. 21:415.
  4. Weller TH, Hanshaw JB. Virologic and clinical observations on cytomegalic inclusion disease. N Engl J Med. 1962 Jun 14. 266:1233-44. [QxMD MEDLINE Link].
  5. Weller TH. The cytomegaloviruses: ubiquitous agents with protean clinical manifestations. I. N Engl J Med. 1971 Jul 22. 285(4):203-14. [QxMD MEDLINE Link].
  6. Schleiss MR, McVoy MA. Overview of congenitally and perinatally acquired cytomegalovirus infections: recent advances in antiviral therapy. Expert Rev Anti Infect Ther. 2004 Jun. 2(3):389-403. [QxMD MEDLINE Link].
  7. Sung H, Schleiss MR. Update on the current status of cytomegalovirus vaccines. Expert Rev Vaccines. 2010 Nov. 9(11):1303-14. [QxMD MEDLINE Link].
  8. Schleiss MR. Congenital cytomegalovirus infection: molecular mechanisms mediating viral pathogenesis. Infect Disord Drug Targets. 2011 Oct. 11(5):449-65. [QxMD MEDLINE Link].
  9. Kimberlin DW, Lin CY, Sanchez PJ, et al. Effect of ganciclovir therapy on hearing in symptomatic congenital cytomegalovirus disease involving the central nervous system: a randomized, controlled trial. J Pediatr. 2003 Jul. 143(1):16-25. [QxMD MEDLINE Link].
  10. Wang D, Shenk T. Human cytomegalovirus virion protein complex required for epithelial and endothelial cell tropism. Proc Natl Acad Sci U S A. 2005 Dec 13. 102(50):18153-8. [QxMD MEDLINE Link].
  11. Ryckman BJ, Jarvis MA, Drummond DD, Nelson JA, Johnson DC. Human cytomegalovirus entry into epithelial and endothelial cells depends on genes UL128 to UL150 and occurs by endocytosis and low-pH fusion. J Virol. 2006 Jan. 80(2):710-22. [QxMD MEDLINE Link].
  12. Sylwester AW, Mitchell BL, Edgar JB, Taormina C, Pelte C, Ruchti F. Broadly targeted human cytomegalovirus-specific CD4+ and CD8+ T cells dominate the memory compartments of exposed subjects. J Exp Med. 2005 Sep 5. 202(5):673-85. [QxMD MEDLINE Link].
  13. Walter EA, Greenberg PD, Gilbert MJ, Finch RJ, Watanabe KS, Thomas ED. Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor. N Engl J Med. 1995 Oct 19. 333(16):1038-44. [QxMD MEDLINE Link].
  14. Miller-Kittrell M, Sparer TE. Feeling manipulated: cytomegalovirus immune manipulation. Virol J. 2009 Jan 9. 6:4. [QxMD MEDLINE Link]. [Full Text].
  15. Schleiss MR. Can we build it better? Using BAC genetics to engineer more effective cytomegalovirus vaccines. J Clin Invest. 2010 Dec. 120(12):4192-7. [QxMD MEDLINE Link].
  16. Ho M. Epidemiology of cytomegalovirus infections. Rev Infect Dis. 1990 Sep-Oct. 12 Suppl 7:S701-10. [QxMD MEDLINE Link].
  17. Pesch MH, Schleiss MR. Emerging concepts in congenital cytomegalovirus. Pediatrics. 2022 Aug 1. 150 (2):[QxMD MEDLINE Link].
  18. Kenneson A, Cannon MJ. Review and meta-analysis of the epidemiology of congenital cytomegalovirus (CMV) infection. Rev Med Virol. 2007 Jul-Aug. 17(4):253-76. [QxMD MEDLINE Link].
  19. Dar L, Pati SK, Patro AR, et al. Congenital cytomegalovirus infection in a highly seropositive semi-urban population in India. Pediatr Infect Dis J. 2008 Sep. 27(9):841-3. [QxMD MEDLINE Link].
  20. Boppana SB, Ross SA, Novak Z, Shimamura M, Tolan RW Jr, Palmer AL. Dried blood spot real-time polymerase chain reaction assays to screen newborns for congenital cytomegalovirus infection. JAMA. 2010 Apr 14. 303(14):1375-82. [QxMD MEDLINE Link].
  21. Kabani N, Ross SA. Congenital cytomegalovirus infection. J Infect Dis. 2020 Mar 5. 221 (Suppl 1):S9-S14. [QxMD MEDLINE Link]. [Full Text].
  22. Leruez-Ville M, Foulon I, Pass R, Ville Y. Cytomegalovirus infection during pregnancy: state of the science. Am J Obstet Gynecol. 2020 Sep. 223 (3):330-49. [QxMD MEDLINE Link].
  23. Dworsky M, Yow M, Stagno S, Pass RF, Alford C. Cytomegalovirus infection of breast milk and transmission in infancy. Pediatrics. 1983 Sep. 72(3):295-9. [QxMD MEDLINE Link].
  24. Hamele M, Flanagan R, Loomis CA, Stevens T, Fairchok MP. Severe morbidity and mortality with breast milk associated cytomegalovirus infection. Pediatr Infect Dis J. 2010 Jan. 29(1):84-6. [QxMD MEDLINE Link].
  25. Bate SL, Dollard SC, Cannon MJ. Cytomegalovirus seroprevalence in the United States: the national health and nutrition examination surveys, 1988-2004. Clin Infect Dis. 2010 Jun 1. 50(11):1439-47. [QxMD MEDLINE Link].
  26. Cannon MJ, Schmid DS, Hyde TB. Review of cytomegalovirus seroprevalence and demographic characteristics associated with infection. Rev Med Virol. 2010 Jul. 20(4):202-13. [QxMD MEDLINE Link].
  27. Adler SP, Starr SE, Plotkin SA, Hempfling SH, Buis J, Manning ML. Immunity induced by primary human cytomegalovirus infection protects against secondary infection among women of childbearing age. J Infect Dis. 1995 Jan. 171(1):26-32. [QxMD MEDLINE Link].
  28. Fowler KB, Pass RF. Risk factors for congenital cytomegalovirus infection in the offspring of young women: exposure to young children and recent onset of sexual activity. Pediatrics. 2006 Aug. 118(2):e286-92. [QxMD MEDLINE Link].
  29. [Guideline] Kaplan JE, Masur H, Holmes KK. Guidelines for preventing opportunistic infections among HIV-infected persons--2002. Recommendations of the U.S. Public Health Service and the Infectious Diseases Society of America. MMWR Recomm Rep. 2002 Jun 14. 51:1-52. [QxMD MEDLINE Link].
  30. Colugnati FA, Staras SA, Dollard SC, Cannon MJ. Incidence of cytomegalovirus infection among the general population and pregnant women in the United States. BMC Infect Dis. 2007 Jul 2. 7:71. [QxMD MEDLINE Link]. [Full Text].
  31. Gunkel J, de Vries LS, Jongmans M, Koopman-Esseboom C, van Haastert IC, Eijsermans MCJ, et al. Outcome of Preterm Infants With Postnatal Cytomegalovirus Infection. Pediatrics. 2018 Feb. 141 (2):[QxMD MEDLINE Link].
  32. Boppana SB, Rivera LB, Fowler KB, Mach M, Britt WJ. Intrauterine transmission of cytomegalovirus to infants of women with preconceptional immunity. N Engl J Med. 2001 May 3. 344(18):1366-71. [QxMD MEDLINE Link].
  33. Schleiss MR. Cytomegalovirus vaccines and methods of production (WO20009049138): the emerging recognition of the importance of virus neutralization at the epithelial/endothelial interface. Expert Opin Ther Pat. 2010 Apr. 20(4):597-602. [QxMD MEDLINE Link].
  34. Dollard SC, Grosse SD, Ross DS. New estimates of the prevalence of neurological and sensory sequelae and mortality associated with congenital cytomegalovirus infection. Rev Med Virol. 2007 Sep-Oct. 17(5):355-63. [QxMD MEDLINE Link].
  35. Bale JF, Miner L, Petheram SJ. Congenital Cytomegalovirus Infection. Curr Treat Options Neurol. 2002 May. 4(3):225-230. [QxMD MEDLINE Link].
  36. Cheeran MC, Lokensgard JR, Schleiss MR. Neuropathogenesis of congenital cytomegalovirus infection: disease mechanisms and prospects for intervention. Clin Microbiol Rev. 2009 Jan. 22(1):99-126, Table of Contents. [QxMD MEDLINE Link].
  37. Williamson WD, Demmler GJ, Percy AK, Catlin FI. Progressive hearing loss in infants with asymptomatic congenital cytomegalovirus infection. Pediatrics. 1992 Dec. 90(6):862-6. [QxMD MEDLINE Link].
  38. Fowler KB, McCollister FP, Dahle AJ, Boppana S, Britt WJ, Pass RF. Progressive and fluctuating sensorineural hearing loss in children with asymptomatic congenital cytomegalovirus infection. J Pediatr. 1997 Apr. 130(4):624-30. [QxMD MEDLINE Link].
  39. Foulon I, Naessens A, Foulon W, Casteels A, Gordts F. A 10-year prospective study of sensorineural hearing loss in children with congenital cytomegalovirus infection. J Pediatr. 2008 Jul. 153(1):84-8. [QxMD MEDLINE Link].
  40. Torpy JM, Burke AE, Glass RM. JAMA patient page. Cytomegalovirus. JAMA. 2010 Apr 14. 303(14):1440. [QxMD MEDLINE Link].
  41. Cannon MJ, Davis KF. Washing our hands of the congenital cytomegalovirus disease epidemic. BMC Public Health. 2005. 5:70. [QxMD MEDLINE Link].
  42. Fowler KB, Dahle AJ, Boppana SB, Pass RF. Newborn hearing screening: will children with hearing loss caused by congenital cytomegalovirus infection be missed?. J Pediatr. 1999 Jul. 135(1):60-4. [QxMD MEDLINE Link].
  43. Horwitz CA, Henle W, Henle G, et al. Clinical and laboratory evaluation of cytomegalovirus-induced mononucleosis in previously healthy individuals. Report of 82 cases. Medicine (Baltimore). 1986 Mar. 65(2):124-34. [QxMD MEDLINE Link].
  44. Barton LL, Mets MB. Congenital lymphocytic choriomeningitis virus infection: decade of rediscovery. Clin Infect Dis. 2001 Aug 1. 33(3):370-4. [QxMD MEDLINE Link].
  45. Gleaves CA, Smith TF, Shuster EA, Pearson GR. Comparison of standard tube and shell vial cell culture techniques for the detection of cytomegalovirus in clinical specimens. J Clin Microbiol. 1985 Feb. 21(2):217-21. [QxMD MEDLINE Link]. [Full Text].
  46. Demmler GJ, Buffone GJ, Schimbor CM, May RA. Detection of cytomegalovirus in urine from newborns by using polymerase chain reaction DNA amplification. J Infect Dis. 1988 Dec. 158(6):1177-84. [QxMD MEDLINE Link].
  47. Ljungman P, Hakki M, Boeckh M. Cytomegalovirus in hematopoietic stem cell transplant recipients. Hematol Oncol Clin North Am. 2011 Feb. 25(1):151-69. [QxMD MEDLINE Link].
  48. Razonable RR. Cytomegalovirus infection after liver transplantation: current concepts and challenges. World J Gastroenterol. 2008 Aug 21. 14(31):4849-60. [QxMD MEDLINE Link].
  49. Boppana SB, Ross SA, Novak Z, Shimamura M, Tolan RW Jr, Palmer AL. Dried blood spot real-time polymerase chain reaction assays to screen newborns for congenital cytomegalovirus infection. JAMA. 2010 Apr 14. 303(14):1375-82. [QxMD MEDLINE Link].
  50. Pass RF, Zhang C, Evans A, et al. Vaccine prevention of maternal cytomegalovirus infection. N Engl J Med. 2009 Mar 19. 360(12):1191-9. [QxMD MEDLINE Link]. [Full Text].
  51. Griffiths PD, Stanton A, McCarrell E, Smith C, Osman M, Harber M. Cytomegalovirus glycoprotein-B vaccine with MF59 adjuvant in transplant recipients: a phase 2 randomised placebo-controlled trial. Lancet. 2011 Apr 9. 377(9773):1256-63. [QxMD MEDLINE Link].
  52. Josephson CD, Caliendo AM, Easley KA, Knezevic A, Shenvi N, Hinkes MT, et al. Blood transfusion and breast milk transmission of cytomegalovirus in very low-birth-weight infants: a prospective cohort study. JAMA Pediatr. 2014 Nov. 168(11):1054-62. [QxMD MEDLINE Link].
  53. Kharfan-Dabaja MA, Boeckh M, Wilck MB, Langston AA, Chu AH, Wloch MK. A novel therapeutic cytomegalovirus DNA vaccine in allogeneic haemopoietic stem-cell transplantation: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Infect Dis. 2012 Apr. 12(4):290-9. [QxMD MEDLINE Link].
  54. Tastad KJ, Schleiss MR, Lammert SM, Basta NE. Awareness of congenital cytomegalovirus and acceptance of maternal and newborn screening. PLoS One. 2019. 14 (8):e0221725. [QxMD MEDLINE Link]. [Full Text].
  55. Adler SP. Cytomegalovirus and child day care. Evidence for an increased infection rate among day-care workers. N Engl J Med. 1989 Nov 9. 321(19):1290-6. [QxMD MEDLINE Link].
  56. Schleiss M, Stanberry L. Herpesvirus infections of the neonatal CNS: Similarities and differences between HSV and CMV. Herpes. 1997. 4:74.
  57. Schleiss MR. Prospects for development and potential impact of a vaccine against congenital cytomegalovirus (CMV) infection. J Pediatr. 2007 Dec. 151(6):564-70. [QxMD MEDLINE Link].
  58. Tabata T, McDonagh S, Kawakatsu H, Pereira L. Cytotrophoblasts infected with a pathogenic human cytomegalovirus strain dysregulate cell-matrix and cell-cell adhesion molecules: a quantitative analysis. Placenta. 2007 May-Jun. 28(5-6):527-37. [QxMD MEDLINE Link].
  59. Zhang C, Buchanan H, Andrews W, Evans A, Pass RF. Detection of cytomegalovirus infection during a vaccine clinical trial in healthy young women: seroconversion and viral shedding. J Clin Virol. 2006 Mar. 35(3):338-42. [QxMD MEDLINE Link].

Author

Mark R Schleiss, MD Minnesota American Legion and Auxiliary Heart Research Foundation Chair of Pediatrics, Professor of Pediatrics, Division Director, Division of Infectious Diseases and Immunology, Department of Pediatrics, University of Minnesota Medical School

Mark R Schleiss, MD is a member of the following medical societies: American Pediatric Society, Infectious Diseases Society of America, Pediatric Infectious Diseases Society, Society for Pediatric Research

Disclosure: Nothing to disclose.

Pharmacy Editor

Mary L Windle, PharmD Adjunct Associate Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Nothing to disclose.

Chief Editor

Russell W Steele, MD Clinical Professor, Tulane University School of Medicine; Staff Physician, Ochsner Clinic Foundation

Russell W Steele, MD is a member of the following medical societies: American Academy of Pediatrics, American Association of Immunologists, American Pediatric Society, American Society for Microbiology, Infectious Diseases Society of America, Louisiana State Medical Society, Pediatric Infectious Diseases Society, Society for Pediatric Research, Southern Medical Association

Disclosure: Nothing to disclose.

Acknowledgements

Leslie L Barton, MD Professor Emerita of Pediatrics, University of Arizona College of Medicine

Leslie L Barton, MD is a member of the following medical societies: American Academy of Pediatrics, Association of Pediatric Program Directors, Infectious Diseases Society of America, and Pediatric Infectious Diseases Society

Disclosure: Nothing to disclose.